Silence Therapeutics PLC ADR (SLN)

Silence Therapeutics PLC ADR is a depositary receipt listed on NASDAQ that reflects the common shares of Silence Therapeutics plc, a biotechnology company focused on RNA interference, or siRNA, research and development. The company is working on therapies intended to affect gene expression in areas such as hematology, cardiovascular disease, and rare diseases. Its pipeline includes Divesiran (SLN124), which is being studied in Phase 2 for polycythemia vera, along with SLN548 for complement-mediated renal diseases. Additional programs include Zerlasiran (SLN360) for cardiovascular disease linked to elevated lipoprotein(a), as well as SLN312, SLN365, and SLN098 for dyslipidemia, hypercholesterolemia, and obesity. The company was founded in 1994, is based in London, and adopted the Silence Therapeutics plc name in 2007.


Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-SLN
$11.36
-42.7% Downside
Overvalued
$19.75
-0.4% Downside
Fair
Fair
0.0%
March 17, 2027
32.0x
2,002.6x
1.233 B
1.16 B
0.0%
85.6%
-15.3
70.5%
Valuation • Fair Value

Silence Therapeutics PLC ADR (NASDAQ-SLN) Fair Value by Valuation Model

Review the available estimates for Silence Therapeutics PLC ADR (NASDAQ-SLN), including Comps Fair Value.

Primary Valuation Read

Fair Value

$11.36

Estimated downside of 42.7% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$11.36

Comparable-company valuation reference.

Analyst Price Target

$19.75

Analysts imply downside of 0.4%.

How to read these valuation models

Use the 4 available valuation references for Silence Therapeutics PLC ADR (NASDAQ-SLN) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Silence Therapeutics PLC ADR (NASDAQ-SLN)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

615 K

Current operating scale indicator.

Revenue Forecast

417.912 K

Forward revenue estimate.

EBITDA

-63.942 M

Current operating profitability reference.

EBITDA Forecast

-58.521 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Silence Therapeutics PLC ADR (NASDAQ-SLN) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Silence Therapeutics PLC ADR (NASDAQ-SLN)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

2

Weak quality score that deserves closer review.

Beneish M-Score

-9.62

No elevated caution signal from this screen.

Altman Z-Score

-15.3

Lower score that deserves closer risk review.

FCF / Net Income

70.5%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Silence Therapeutics PLC ADR (NASDAQ-SLN). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Silence Therapeutics PLC ADR (NASDAQ-SLN)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

March 17, 2027

Days to Earnings

124

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Silence Therapeutics PLC ADR (NASDAQ-SLN), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Silence Therapeutics PLC ADR (NASDAQ-SLN) Stock Forecast & Technical Outlook

Review Silence Therapeutics PLC ADR (NASDAQ-SLN) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Silence Therapeutics PLC ADR (NASDAQ-SLN) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Silence Therapeutics PLC ADR (NASDAQ-SLN) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Silence Therapeutics PLC ADR (NASDAQ-SLN) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Silence Therapeutics PLC ADR (NASDAQ-SLN) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Silence Therapeutics PLC ADR (NASDAQ-SLN) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Silence Therapeutics PLC ADR (NASDAQ-SLN)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Silence Therapeutics PLC ADR (NASDAQ-SLN) has a Hold consensus, with 1 buy, 4 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 4
Sell 0
FAQ • Fast Investor Answers

Silence Therapeutics PLC ADR (NASDAQ-SLN) Stock FAQ

Data-supported answers about Silence Therapeutics PLC ADR (NASDAQ-SLN), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$11.36
Estimated downside 42.7%
Valuation Rating
Overvalued
Estimated downside of 42.7%
Analyst Target
$19.75
Implied downside 0.4%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Silence Therapeutics PLC ADR (NASDAQ-SLN) is $11.36. This implies an estimated downside of 42.7% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 42.7% versus the current market price.

The available analyst price target for Silence Therapeutics PLC ADR (NASDAQ-SLN) is $19.75. The analyst target implies estimated downside of 0.4%.

The current financial health read for Silence Therapeutics PLC ADR (NASDAQ-SLN) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Silence Therapeutics PLC ADR (NASDAQ-SLN) is March 17, 2027.

The latest available data indicates no current dividend yield for Silence Therapeutics PLC ADR (NASDAQ-SLN).

The current market capitalization listed for Silence Therapeutics PLC ADR is 1.233 B.

The current enterprise value listed for Silence Therapeutics PLC ADR is 1.16 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Silence Therapeutics PLC ADR is NASDAQ-SLN, and the stock is listed on NASDAQ.

Silence Therapeutics PLC ADR (NASDAQ-SLN) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Silence Therapeutics PLC ADR is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Silence Therapeutics PLC ADR is 85.6%. Free float helps investors understand how much of the share base is available for public trading.